Hepion shelves Phase II NASH trial amid shallow cash resources
Hepion Pharmaceuticals has called it quits on a Phase IIb trial investigating the biotech’s lead drug candidate for the treatment…
Hepion Pharmaceuticals has called it quits on a Phase IIb trial investigating the biotech’s lead drug candidate for the treatment…
Inhibikase Therapeutics is eying pulmonary arterial hypertension (PAH) as a potential indication for its imatinib alternative IkT-001Pro. In an 18…
Amid a US regulatory landscape promoting collaboration in cell and gene therapy development, SpliceBio’s CEO Miquel Vila-Perelló has questioned why…
Acorda Therapeutics has been delisted from the Nasdaq Stock Market as a result of non-compliance with Nasdaq’s listing rules. Nasdaq…
Sanofi has moved its natural killer (NK) cell engager candidate SAR443579/IPH6101 to a Phase II trial evaluating the drug’s use…
The US Food and Drug Administration (FDA) has granted Candel Therapeutics’ immunotherapy candidate CAN-2409 (aglatimagene besadenovec) orphan drug designation for…
Vertex Pharmaceuticals has agreed to acquire biotech Alpine Immune Sciences for $4.9bn, joining the growing number of pharma spending big on…
The US Food and Drug Administration (FDA) has granted orphan drug designation for Lisata Therapeutics’s LSTA1 (certepetide) for the treatment…
Seaport Therapeutics has entered the neuropsychiatry treatment space after emerging with $100m from a financing round. ARCH Venture Partners and…
Sensorion has secured €14.8m ($16m) from its investors to advance its gene therapy programmes for the treatment of deafness and…